Biotech Values

[biomaven0]

There were a number of comments from AKBA and AKBA IR that lead many investors to believe that this would give AKBA a lock on supplying Fresenius US. Nowhere did they state that it was quite unclear whether the drug would be included in the bundle - again only a very few sophisticated investors with detailed knowledge of FGEN understood the implications of their assumption.

So yes, the PR itself may have been correct on its face - but the way they presented this deal was still misleading in my judgement.

Peter